Antimuscarinics are the treatment of choice for patients suffering from overactive bladder syndrome (OAB). Clinical experience and the literature support the efficacy, tolerability, and safety of each agent. With increasing data and educational and marketing efforts, many health care providers are uncertain which antimuscarinic should be prescribed first. It is important to recognize that there is not one superior agent, and that the individual response to each antimuscarinic is highly variable. This paper uses peer-reviewed literature to elucidate various agents with respect to efficacy, tolerability, and safety, to help readers understand the pros and cons associated with each drug so they may better manage patients with OAB.

Written by
MacDiarmid SA.

Reference
Curr Urol Rep. 2007 Sep;8(5):364-9

PubMed Abstract
PMID:17880834

UroToday.com Overactive Bladder Section

Please log-in or register in order to submit comments.

Powered by AkoComment!